3B BlackBio DX Limited is an Indian biotech and diagnostics company focused on molecular diagnostics (TRUPCR PCR kits, enzymes and reagents), Next‑Gen Sequencing assays (TRUNGS), and rapid tests (TRURAPID), while retaining legacy agrochemical operations; the company recently acquired Coris BioConcept (Belgium) and operates manufacturing and R&D facilities recognized by DSIR and ISO standards.

Management reported consolidated nine‑months revenue of INR99.06 crore (including Coris) versus INR64.80 crore earlier, with 3B standalone growing around 11.8% year‑on‑year and management guiding consolidated revenue growth of 10%–15% for the full year, while exports are expected to outpace domestic growth at 15%–20% given strengthened European and other geographies.

The Coris acquisition materially changes revenue composition and capabilities: Coris contributed approximately INR24 crore in the quarter, including a ~INR8.8 crore one‑off from a HAT government supply contract, and management is pursuing US FDA clearance and selective IVDR certifications to convert regulatory investment into market access for Europe and the US.

Competition intensity is rising as adjacent diagnostic players enter molecular diagnostics attracted by higher margins, but 3B emphasizes SKU breadth, technical support, and workflow efficiency to retain stickiness; management is balancing organic R&D (multiplex panels, dPCR, sample‑to‑answer) with inorganic growth via acquisitions to protect and expand market share.

The company holds cash and acquisition firepower (management cited roughly INR190 crore cash position with INR130–140 crore available for acquisitions while retaining reserves), intends to prioritize profitable scale and M&A integration, and flags short‑term EBITDA pressure from merger‑related one‑offs while targeting improved profitability at Coris next year.